TRT Blood Work Results Explained

Why Your Labs Look Different on TRT

When you get blood work back on testosterone replacement therapy, the first thing most patients notice is a sea of bold "HIGH" flags next to their results. Your total testosterone reads 750 ng/dL and the lab report marks it out of range. Your hematocrit is 49% and the software flags it in red. It is easy to panic — but almost all of this is expected and, more importantly, normal for someone on TRT.

Standard lab reference ranges are calculated from population distributions of untreated men. The "normal" range for total testosterone — typically 300–1,000 ng/dL depending on the lab and assay — represents the bell curve of men who are not on therapy. The lower end of that range includes men who are genuinely hypogonadal, and the upper end includes men at their natural peak in their early twenties. When you are on TRT, your goal is not to fall within the average of the untreated population. Your goal is to reach a therapeutic range that eliminates symptoms while staying within safe physiological limits.

This distinction matters every time you read a lab report. The numbers on the page need to be interpreted through the lens of someone on exogenous testosterone, not someone walking in off the street for a routine physical. Your prescribing provider should understand this, but patients who read their own labs often don't — and that leads to unnecessary worry, dose adjustments based on misread flags, and confusion when providers who aren't hormone specialists react to the numbers without context.

The sections below walk through every major marker you'll see on a TRT panel, what each one measures, what the therapeutic target actually is, and what signals warrant a conversation with your clinic.

Total Testosterone

Total testosterone is the sum of all testosterone in your blood — the fraction bound to proteins like SHBG and albumin, plus the small free fraction that is actually biologically active. It is the headline number on your panel and the one most clinicians use to gauge whether your dose is in range.

Before TRT, the average adult male sits somewhere between 300 and 700 ng/dL, with healthy younger men sometimes reaching 900 ng/dL naturally. On TRT, most clinical protocols target a total testosterone of 600–900 ng/dL, measured at trough — meaning drawn the morning of your next injection before you take your dose, or roughly 24 hours after a daily topical application. This trough measurement gives you the floor of your weekly or biweekly cycle, not the peak, which can run considerably higher depending on your injection frequency and ester.

If your trough total testosterone is sitting below 500 ng/dL and you are still symptomatic — low energy, poor libido, mood instability — your dose likely needs adjustment. If it is routinely running above 1,100 ng/dL at trough, that warrants a closer look, both because elevated testosterone accelerates aromatization (driving up estradiol) and because erythrocytosis risk increases with dose. Neither scenario is an emergency, but both are conversations to have with your prescriber.

How often to test: most experienced TRT clinics recheck labs at 6–8 weeks after any dose change, then every 6 months once stable. If you are newly started on therapy, testing before the 6-week mark is largely uninformative — your levels have not reached steady state yet.

Timing your blood draw matters more than most patients realize. A total testosterone result drawn 48 hours after a weekly injection will look dramatically different than one drawn the morning before your next dose. Always draw at trough, and note the timing on your lab order.

Free Testosterone

Total testosterone tells you how much testosterone is circulating in your blood, but not how much is available to your cells. That is where free testosterone comes in. Only about 2–3% of circulating testosterone is unbound and free to interact with androgen receptors. The rest is tied up — roughly 44% to albumin (loosely bound and partially bioavailable) and about 54% to sex hormone-binding globulin (tightly bound and largely unavailable).

You can have a total testosterone of 900 ng/dL and still feel like symptoms haven't resolved if your SHBG is very high, because most of that testosterone is locked away from tissue. Conversely, a patient with lower SHBG and a total T of 650 ng/dL might have excellent free testosterone and feel completely optimized.

There are two ways free T gets reported: a calculated value (derived from total T, SHBG, and albumin using the Vermeulen or Ly formulas) and a direct measurement by equilibrium dialysis. Equilibrium dialysis is more accurate but less commonly ordered. Most clinics use the calculated value, which is sufficient for clinical monitoring. A free testosterone in the range of 15–25 pg/mL (or 1.5–2.5% of total testosterone) is generally considered optimal on TRT, though some men feel best at the higher end of that range.

If your free T is lagging despite a reasonable total T number, the culprit is usually elevated SHBG — which is addressed in its own section below.

Estradiol (E2)

Estradiol is the form of estrogen that matters most in men on TRT, and it is one of the most mismanaged markers in the TRT space. When you add exogenous testosterone, some of it converts to estradiol through an enzyme called aromatase, which is found primarily in fat tissue, liver, and the brain. More testosterone in the system means more raw material for aromatization — so estradiol rises on TRT, often substantially.

The instinct in early TRT protocols was to aggressively suppress estradiol using aromatase inhibitors (AIs) like anastrozole. This turned out to be wrong for most patients. Estradiol in men serves real physiological functions: it is critical for bone density, cardiovascular health, libido, cognitive function, and joint lubrication. Driving it too low causes its own set of problems.

High E2 symptoms include water retention (puffy face, soft tissue), moodiness or emotional sensitivity, nipple tenderness or sensitivity, and in some cases reduced libido or erectile dysfunction despite good testosterone levels. Low E2 symptoms are often more severe: joint aches and creaking, flat mood or depression, poor libido, and in the longer term, risk of bone density loss.

The commonly referenced target range for men on TRT is 20–40 pg/mL on a sensitive estradiol assay (sometimes written as E2 sensitive or LC/MS/MS). This is different from the standard immunoassay used for women — if your lab result says "estradiol" without specifying the assay type, it may be unreliable in the male range. Always request the sensitive assay when ordering E2 for a man on TRT.

For a full discussion of how to interpret estradiol results and when AIs are actually warranted, see our guide on estradiol management on TRT.

Hematocrit

Testosterone stimulates erythropoiesis — the production of red blood cells — through pathways involving EPO (erythropoietin) and direct effects on bone marrow. This is why TRT reliably raises hematocrit, which measures the percentage of your blood volume made up of red blood cells. It is one of the most predictable and consistent effects of testosterone therapy, and it is also one that requires monitoring because it carries real risk at the high end.

Normal hematocrit in untreated men runs roughly 40–50%. On TRT, values of 48–52% are common and not concerning on their own. The concern threshold is generally set at 52–54%, at which point blood viscosity has increased enough to raise the risk of thromboembolic events — blood clots, stroke, and deep vein thrombosis. The exact cutoff varies by clinic and guidelines, but most practitioners get attentive above 52% and intervene above 54%.

The two main management strategies are dose reduction (less testosterone means less erythropoietic stimulation) and therapeutic phlebotomy — donating blood or having blood drawn to mechanically reduce red cell mass. Therapeutic phlebotomy is effective but is not a permanent fix if the underlying dose continues to drive overproduction. Staying well hydrated can reduce apparent hematocrit somewhat, since dehydration concentrates the blood, but hydration is not a substitute for clinical management at genuinely elevated levels.

Hematocrit should be checked at baseline before starting TRT, then at 6–8 weeks after initiation or any dose increase, and every 6 months once stable.

PSA (Prostate-Specific Antigen)

PSA is a protein produced by prostate tissue, and elevated levels have long been associated with prostate cancer screening. This has historically made patients and physicians nervous about TRT — but the relationship between testosterone and prostate cancer risk is more nuanced than the fear suggests.

What is important to know clinically: a baseline PSA before starting TRT is essential. You need a starting point to detect change over time. A modest rise in PSA after initiating TRT is normal — typically 0.3–0.5 ng/mL — because the prostate responds to restored androgens like any other androgen-sensitive tissue. This is not a cancer signal; it is a pharmacological response.

What warrants investigation is a rapid or large increase: a rise of more than 1.0–1.4 ng/mL within the first 12 months of therapy, a PSA velocity above 0.75 ng/mL per year on stable therapy, or an absolute value above 4.0 ng/mL (or 3.0 ng/mL in men under 60 with other risk factors). Those findings call for urological evaluation — not panic, but follow-up.

For most men on well-managed TRT, PSA remains stable and unremarkable year over year. Check it annually once on stable therapy, or sooner if symptoms of urinary obstruction develop.

SHBG (Sex Hormone-Binding Globulin)

SHBG is a glycoprotein produced primarily by the liver, and it binds tightly to both testosterone and estradiol, rendering what it binds biologically inactive. Understanding your SHBG level is key to understanding why your free testosterone may not match your total testosterone.

High SHBG (above 50–60 nmol/L) is common in older men, in men with liver or thyroid conditions, and in men who consume alcohol regularly. High SHBG binds a greater proportion of circulating testosterone, leaving less free. Men with high SHBG often need higher total testosterone targets on TRT to maintain adequate free T, and they typically do better with more frequent dosing intervals (twice weekly or more) to sustain stable peaks without the level dropping too far at trough.

Low SHBG (below 18–20 nmol/L) is associated with obesity, insulin resistance, hypothyroidism, and exogenous anabolic steroid use. Low SHBG means more free testosterone per unit of total testosterone — which can be an advantage — but it also means faster clearance, so levels fluctuate more between doses and the active fraction can be difficult to keep stable.

Lifestyle factors that raise SHBG: regular moderate exercise, adequate sleep, zinc intake, and maintaining a healthy body weight. Factors that lower it include obesity, high insulin levels, and caloric excess. SHBG is worth tracking as part of any full TRT panel.

TRT Lab Reference Table

The table below shows standard lab reference ranges alongside practical TRT targets and the flags that typically prompt clinical action.

Reading Your Lab Report: Common Confusions

The single most common source of confusion for TRT patients reading their own labs is the "HIGH" flag next to total testosterone. Labs generate these flags algorithmically against population reference ranges — they are not clinical assessments. A result of 820 ng/dL will get flagged as high at some labs because it exceeds their 95th percentile for untreated men. That flag means nothing for someone on TRT whose therapeutic target is 700–900 ng/dL. The flag is descriptive, not diagnostic.

Reference ranges also differ meaningfully between labs. LabCorp and Quest use different assay methodologies and different reference populations, which means a result of 340 pg/mL on one can look very different from the same result on another when you account for units, methodology, and calibration. Always note which lab performed the test when comparing results over time, and ideally use the same lab for serial monitoring.

Draw timing is the other major confounder. Testosterone levels fluctuate throughout the day — they peak in the morning and are typically 20–30% lower by evening. For men on injections, levels also rise and fall across the dosing cycle. A blood draw 24 hours after a weekly injection of testosterone cypionate will be at peak; the same draw taken 7 days later immediately before the next dose is at trough. These two results from the same person on the same dose can differ by 200–400 ng/dL. Clinical decisions should be made on trough draws unless your protocol uses more frequent injections that minimize the peak-to-trough swing.

When comparing your results to any reference — including the table above — always ask: what was my draw timing relative to my dose? Was this a morning draw? Am I comparing to the same lab as last time? Getting the context right matters as much as the number itself.